Abstract: Addition of ammonium stabilized colloidal silica, borax and boric acid to the distilled water in which dental porcelain is fired greatly increases the firing range by reducing "balling" or edge rounding, and flow deformation. Greatly increased machinability and indefinitely prolonged green-biscuit strength is also obtained by the use of the present additive without deleterious effects on the porcelain.

Abstract: An apparatus for countercurrent chromatography consisting of a coiled separation column which is rotated about the axis about which is it wound and the axis is also rotated about a main axis. The embodiments of the invention are based on the fact that the pattern of the centrifugal force field greatly changes with the ratio of the two radii of rotation and depending on the particular effect desired, the apparatus is configured to achieve the most effective force field to gain the effect. The separation column is a tube helix wound around a flexible core member which can be wound onto the coil holder in various orientations to further effect the desired results.

Abstract: A process of pretreating a lower alkyl cellulose, such as ethyl cellulose, which is to be used in microencapsulation of sodium fluoride for dental purposes. This process comprises dispersing a predetermined quantity of lower alkyl cellulose in an aqueous mineral acid, such as HCl, and stirring and aqueous washing of the cellulose such that the pH of the product is adjusted to 6.0 or less. This product is later dissolved in a BTX (benzene, toluene, xylene) solvent such as toluene. Sodium fluoride is added and process steps such as baffle stirring and drying are utilized to produce microencapsulation of the sodium fluoride with the lower alkyl cellulose. The process produces an encapsulating material of optimum sodium content and gives release time in water of 2.3-7.0 hours for the sodium fluoride.

Abstract: A device for removing the stopper from the top of a test tube without exposing the user to hazardous aerosols. The stoppered test tube is inserted upwardly through a vertical passage leading to a chamber. A horizontal air cylinder has a piston rod extending into the chamber, with a pivoted stopper-removing plunger member extending over the passage and having a tail portion which is sealingly engageable with a normally vented sensor nozzle responsive to contact of the top of the stoppered test tube with the plunger member. Closure of the sensor nozzle activates a fluidic back pressure switch, which in turn actuates a fluidic control circuit having two slide valves which respectively operates the air cylinder and simultaneously connects a vacuum source to the chamber. A horizontal slide sensor in the vertical passage is extended to engage the test tube and prevents retraction of the plunger member.

Abstract: A portable neutron spectrometer/kerma-rate meter for the measurement of the fast neutron component of mixed n-.gamma. fields in the 1 to 15 MeV neutron energy range. The system includes an organic scintillation detector, pulse shape discrimination circuitry, a 1.4 .mu.sec multichannel analyzer, an 8-bit microcomputer, and appropriate displays. The instrument is capable of both gathering and processing recoil-proton pulse-height data in the field.

Abstract: 5'-Deoxy-5'-(isobutylthio)-3-deazaadenosine and a method for preparation of same. In the preparation, 3-deazaadenosine is utilized as a starting material and is chlorinated at the 5' position. Subsequently, the chloro group is converted to isobutylthio by reaction with isobutyl mercaptan in ethanol containing sodium methoxide giving the desired compound.A most preferred starting material, i.e., 3-deazaadenosine, was prepared according to the method of Montgomery et al, J. Heterocyclic Chem., 14:195 (1977). The key fusion of this process is 4,6-dichloroimidazo[4,5-c]pyridine with 1,2,3,5-tetra-O-acetyl-.beta.-D-ribofuranose, which, after removal of protective groups and reductive dechlorination of the chlorine at 6, gives 3-deazaadenosine.

Abstract: The present invention is an improved multi-step process for the production of 9-.beta.-D-arabinofuranosyl-2-fluoroadenine (2-F-AraA) and an improvement over the process of Montgomery and Hewson, J. Med. Chem., 12:498 (1969). This compound is an important tool in antitumor therapy and has shown activity against leukemia L1210 and P388 in animals as well as being a potent antiviral agent. Its therapeutic effectiveness occurs because 2-F-AraA is not a substrate for adenosine deaminase which vitiated against the activity of the parent compound 9-.beta.-D-arabinofuranosyladenine (araA) as indicated in experimental animal cancers.An advantage of making 2-F-AraA by the present process is that there is a sharply increased yield based on the chlorosugar up to about 400 percent.

Abstract: A system for obtaining a hemoglobin-oxygen equilibrium curve for a sample of concentrated hemoglobin solution or whole blood. Gaseous oxygen and/or nitrogen is used to oxygenate or deoxygenate the sample. The exchange takes place across a gas-receiving cup-shaped semipermeable membrane in a temperature-controlled chamber containing the sample, in an annular space defined between the cup-shaped gas-receiving membrane and the chamber wall. The rate of oxygen transport into and out of the sample is continuously calculated by means of a microcomputer. Simultaneously the solution pO.sub.2 is measured by means of a Clark electrode exposed to the sample. From the oxygen transport rate calculation and the pO.sub.2 measurement, the percent O.sub.2 saturation is calculated and is plotted against the change in pO.sub.2. Oxygen can be exchanged bidirectionally with the sample across the semipermeable membrane, which is positioned concentrically in a cylindrical sample cavity.

Abstract: A nebulizer to produce a finely dispersed aerosol from a solution passing over its surface comprises a chamber through which a gas, such as air, is adapted to be blown. The chamber has an outlet conduit, and mounted in the chamber facing the outlet conduit is an inclined upright bar formed with a longitudinal V-groove having a central gas exit port to which is connected a gas input delivery tube. A sample introduction tube is connected to the top end of the bar at said V-groove to admit sample solution thereto. The side walls of the V-groove below the gas exit port are lower in height than above the gas exit port to prevent aerosol droplets from settling on the walls and from interfering with the entry of the aerosol into the exit port. An impactor rod is adjustably mounted on the lower portion of the bar and is adjusted so that its top end is in front of the gas exit port.

Abstract: The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane) platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt.The 4-carboxyphthalato(1,2-diaminocyclohexane)-platinum(II) and alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY) and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component.

Abstract: The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt.The 4-carboxyphthalato(1,2-diaminocyclohexane)platinum(II) and alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY) and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component.

Abstract: The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt.The 4-carboxyphthalato(1,2-diaminocyclohexane)platinum(II) and alkali metal salts thereof may be combined in multiple drug regimen with substantially improved yield cures over the parent compound. For example, the compound denoted Pt-307 may be combined in a dual regimen with cyclophosphamide (CY) and in a triple drug regimen of Pt-307 plus cyclophosphamide (CY) and either 5-fluorouracil (5-FU) or hydroxyurea (HU) as the third component.

Abstract: 4-Carboxyphthalato(1,2-diaminocyclohexane)platinum(II) (and alkali metal salts thereof) has shown antileukemic activity in mice against murine leukemia L1210. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added 5-fluorouracil (5-FU) (75 mg/kg of body weight) or hydroxyurea (HU) (1000 mg/kg of body weight). Some previous platinum chelate compounds show dosage limitation due to renal impairment but the free carboxyl of the present Pt compound offers a possible route of oral administration and absorption by the stomach.The Pt compound may be prepared by reacting the known dichloro(1,2-diaminocyclohexane)platinum(II) (NSC 194814) with silver nitrate to replace chloro with nitro. Subsequently, benzene tricarboxylic acid is added to form an off-white precipitate (2 hrs, dark, 5.degree. C.) of the desired product which is preferably utilized as the alkali metal salt.

Abstract: A series of compounds showing high antileukemic activity against P388 murine leukemia and increased aqueous solubility due to substitution of --OH for the known --NH.sub.2 at the 3' position of the hexopyranose sugar, i.e., daunosamine.These compounds are coupled products of aglycon selected from daunomycinone, desmethoxy daunomycinone, adriamycinone and carminomycinone. These compounds are coupled at the 0-7 position of the aglycon with an .alpha.

Abstract: A flow indicating attachment for a transparent rotameter column containing a visible float movable in accordance with the rate of fluid flow through the column consists of a reciprocating scanner moving parallel to the column in a flow rate range including the range of float movement and coupled to a potentiometer forming a synchronous analog scanning signal which is furnished to a recorder. The scanner has a photoelectric float-sensing assembly including a photocell connected in the analog scanning signal circuit. When the sensing assembly is shaded by the rotameter float, it produces an abrupt dip in the recorded analog scanning signal, thus providing a recorded indication of the float's position in the range covered by the track of the reciprocating scanner.

Abstract: A handling device for enabling a technician to dialyze a solution without direct contact with the solution to be dialyzed. The device comprises a polycarbonate rod having an internal bore and a test tube gripping element at one end. At the other end is clamped a section of dialysis tubing, there being a passageway from the test tube-gripping end through the internal bore and into the dialysis tubing. The dialysis tubing is knotted to form a dialysis bag. The rod is manipulated to grippingly engage over a test tube containing the solution to be dialyzed and the test tube is inverted to transfer its contents to the dialysis bag, after which the device is supported in inverted position with the bag in a dialysis bath. After dialysis, the device is removed and reversed, returning the dialyzed solution to the test tube.

Abstract: A system for creating projected visual motion effects for filming or videotaping, with the use of still projection equipment, involves projecting a still image on a screen from a slide projector, projecting a second image on the screen, superimposed on the first image, and causing the projected second image to move rectilinearly at a controlled variable speed and in a selected direction over the first projected still image. This movement is accomplished with a "crawler" assembly having a transparent rectilinearly movable carrier panel carrying the second image over the stage surface of a standard overhead projector, or a light box, constituting the second image light source. The illuminated second image is directed to the screen by an overhead lens and suitably angled mirror. The transparent carrier is driven by a variable-speed reversible motor through a changeable worm gear drive assembly coupled to friction drive rollers engaging the carrier, which is slidably supportingly retained in a guide frame.

Abstract: This invention relates to a process for the production of 4a-aryldecahydroisoquinolines where the aryl group is selected as 3-methoxy phenyl. These compounds are morphine analogs and show utility similar to the known morphine, codeine, and thebaine. In this process particular novelty is asserted for the production of a nipecotic ester ethyl 4-(3'-methoxyphenyl)-1-methyl piperidine-3-carboxylate. Furthermore, novelty is asserted for the step of conversion of the nipecotates through cyclization to cis- or trans-tert-butyl 1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline-7-carboxylat e, which may also be easily converted to the keto amide, trans-1,6-dioxo-4a-(3'-methoxyphenyl)-2-methyldecahydroisoquinoline.

Abstract: A method of utilizing 9-.beta.-D-arabinofuranosyl-2-fluoroadenine, known as 2-F-AraA (NSC 118218), in the treatment of murine leukemia and as an antiviral agent for DNA viruses, such as DNA viruses Herpes Simplex Virus Type I and Vaccinia virus grown in H.Ep-2 cells in culture. An operable dosage for utilization of 2-F-AraA is a treatment span of 1-10 days with the dosage 2-8 times per day at 8-400 mg/kg/dose. It has been further found that a single dosage on days 1, 5, and 9 based on a 10-day treatment schedule gave satisfactory results.

Abstract: A device for blowing powder onto teeth, the device consisting of a handpiece in the form of a housing connected to a compressed air source and having a discharge nozzle member which can be inserted in a patient's mouth and can be directed towards the patient's teeth. The housing has a powder reservoir with a bottom supply duct. An apertured shuttle bar is reciprocably slidably mounted beneath said duct and has a metering hole registrable with said supply duct and then, by longitudinally moving the bar, with a discharge conduit arranged to receive compressed air from the source so as to discharge a metered amount of powder in said hole into the nozzle member for delivery to the patient's teeth.